Equimune® Immunotherapy an Option for EHV-1

8 May 2023

Napanee, Ontario, Canada – NovaVive Inc., an animal health immunobiology company, offers a USDA-approved immunotherapeutic, Equimune®, which has been recommended as a preventative treatment in horses exposed to Equine Herpes Virus (EHV-1). EHV-1 outbreaks are occurring with increasing frequency, particularly at horse shows and competitions.

EHV-1 is spread from horse to horse through contact with nasal discharge or spread as aerosol droplets. Distance between horses should be maintained whenever possible. Sharing of grooming and feeding equipment is discouraged because EHV-1 can also be spread on tack, clothing, and other equipment.

Equimune is a mycobacterium cell wall fraction (MCWF) immunostimulant that is approved by the USDA for the treatment of Equine Respiratory Disease Complex (ERDC) of viral origin. Herpes Virus is one of the common causes of ERDC, along with influenza A equine-1 (H7N7) and influenza A equine-2 (H3N8). A single, IV dose of Equimune enhances the production of IL-1, one of the body’s natural adjuvants. IL-1 activates the body’s immune system in response to antigens from viral pathogens. Equimune stimulates the innate and specific immune responses, as needed, for several days.

About NovaVive Inc.

NovaVive is a private company founded in July, 2014. The Company has an advanced veterinary immunotherapeutic platform based on mycobacterium cell wall fraction (MCWF) technology with 5 regulator-approved products in the USA. One formulation has been developed as an anticancer therapy in dogs and horses. Other formulations have demonstrated the capability of reducing the reliance on antibiotics in the treatment of bacterial diseases of horses and cattle or effectively treating viral equine respiratory disease. For more information about the Company, please visit www.NovaVive.ca, or contact:

Graeme McRae
Phone/text: 613-391-3837


Jennifer Shea
Phone/text: 613-391-2097

Sign up to stay up-to-date with NovaVive news.